| Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication F Christ, A Voet, A Marchand, S Nicolet, BA Desimmie, D Marchand, ... Nature chemical biology 6 (6), 442-448, 2010 | 559 | 2010 |
| The Saccharomyces cerevisiae EHT1 and EEB1 genes encode novel enzymes with medium-chain fatty acid ethyl ester synthesis and hydrolysis capacity SM Saerens, KJ Verstrepen, SD Van Laere, DFRTJM Voet, AR Van v P J Biol Chem 281, 4446-4456, 2006 | 355 | 2006 |
| Reconstruction of ancestral metabolic enzymes reveals molecular mechanisms underlying evolutionary innovation through gene duplication K Voordeckers, CA Brown, K Vanneste, E van der Zande, A Voet, S Maere, ... PLoS biology 10 (12), e1001446, 2012 | 247 | 2012 |
| Fragment based drug design: from experimental to computational approaches A Kumar, A Voet, KYJ Zhang Current medicinal chemistry 19 (30), 5128-5147, 2012 | 201 | 2012 |
| Pharmacophore modeling: advances, limitations, and current utility in drug discovery X Qing, X Yin Lee, J De Raeymaeker, J RH Tame, K YJ Zhang, ... Journal of Receptor, Ligand and Channel Research, 81-92, 2014 | 182 | 2014 |
| Identification of the LEDGF/p75 binding site in HIV-1 integrase K Busschots, A Voet, M De Maeyer, JC Rain, S Emiliani, R Benarous, ... Journal of molecular biology 365 (5), 1480-1492, 2007 | 181 | 2007 |
| FraC nanopores with adjustable diameter identify the mass of opposite-charge peptides with 44 dalton resolution G Huang, A Voet, G Maglia Nature communications 10 (1), 835, 2019 | 179 | 2019 |
| Androgen receptor antagonists for prostate cancer therapy C Helsen, T Van den Broeck, A Voet, S Prekovic, H Van Poppel, S Joniau, ... Endocrine-related cancer 21 (4), T105-T118, 2014 | 175 | 2014 |
| An integrated map of HIV genome-wide variation from a population perspective G Li, S Piampongsant, NR Faria, A Voet, AC Pineda-Peña, R Khouri, ... Retrovirology 12, 1-18, 2015 | 168 | 2015 |
| Virus evolution reveals an exclusive role for LEDGF/p75 in chromosomal tethering of HIV A Hombrouck, J De Rijck, J Hendrix, L Vandekerckhove, A Voet, ... PLoS pathogens 3 (3), e47, 2007 | 166 | 2007 |
| Computational design of a self-assembling symmetrical β-propeller protein ARD Voet, H Noguchi, C Addy, D Simoncini, D Terada, S Unzai, SY Park, ... Proceedings of the National Academy of Sciences 111 (42), 15102-15107, 2014 | 135 | 2014 |
| Target identification of small molecules using large-scale CRISPR-Cas mutagenesis scanning of essential genes JE Neggers, B Kwanten, T Dierckx, H Noguchi, A Voet, L Bral, K Minner, ... Nature Communications 9 (1), 502, 2018 | 118 | 2018 |
| Guards of the great wall: bacterial lysozyme inhibitors L Callewaert, JM Van Herreweghe, L Vanderkelen, S Leysen, A Voet, ... Trends in microbiology 20 (10), 501-510, 2012 | 117 | 2012 |
| The effect of F877L and T878A mutations on androgen receptor response to enzalutamide S Prekovic, ME van Royen, ARD Voet, B Geverts, R Houtman, D Melchers, ... Molecular cancer therapeutics 15 (7), 1702-1712, 2016 | 116 | 2016 |
| Duplication of a promiscuous transcription factor drives the emergence of a new regulatory network K Pougach, A Voet, FA Kondrashov, K Voordeckers, JF Christiaens, ... Nature Communications 5 (1), 4868, 2014 | 78 | 2014 |
| Functional conservation of HIV-1 Gag: implications for rational drug design G Li, J Verheyen, SY Rhee, A Voet, AM Vandamme, K Theys Retrovirology 10, 1-11, 2013 | 75 | 2013 |
| The transcriptional co-activator LEDGF/p75 displays a dynamic scan-and-lock mechanism for chromatin tethering J Hendrix, R Gijsbers, J De Rijck, A Voet, J Hotta, M McNeely, J Hofkens, ... Nucleic acids research 39 (4), 1310-1325, 2011 | 73 | 2011 |
| Repurposing the antidepressant sertraline as SHMT inhibitor to suppress serine/glycine synthesis–addicted breast tumor growth SL Geeraerts, KR Kampen, G Rinaldi, P Gupta, M Planque, N Louros, ... Molecular cancer therapeutics 20 (1), 50-63, 2021 | 64 | 2021 |
| In silico, in vitro and cellular analysis with a kinome-wide inhibitor panel correlates cellular LRRK2 dephosphorylation to inhibitor activity on LRRK2 R Vancraenenbroeck, J De Raeymaecker, E Lobbestael, F Gao, ... Frontiers in molecular neuroscience 7, 51, 2014 | 62 | 2014 |
| Biochemical and structural characterization of TLXI, the Triticum aestivum L. thaumatin-like xylanase inhibitor E Fierens, K Gebruers, ARD Voet, M De Maeyer, CM Courtin, JA Delcour Journal of Enzyme Inhibition and Medicinal Chemistry 24 (3), 646-654, 2009 | 60 | 2009 |
zeger debyserKU Leuven在 med.kuleuven.be 的电子邮件经过验证